Treatment of cognitive deficits in schizophrenia - Part 2: Pharmacological strategies

被引：5
|
作者：
Roesch-Ely, D. [2 ]
Pfueller, U. [1 ,2 ]
Mundt, C. [2 ]
Mueller, U. [3 ]
Weisbrod, M. [1 ,2 ]
机构：
[1] SRH Klinikum Karlsbad Langensteinbach, Klin Psychiat & Psychotherapie, Karlsbad, Germany
[2] Univ Klinikum Heidelberg, Klin Allgemeine Psychiat, Zentrum Psychosoziale Med, D-69115 Heidelberg, Germany
[3] Univ Cambridge, Addenbrookes Hosp, Dept Psychiat, Cambridge CB2 1TN, England
来源：
NERVENARZT | 2010年 / 81卷 / 05期
关键词：
Cognition-enhancing drugs; Cognition; Schizophrenia; Psychopharmacology; Treatment; RANDOMIZED CONTROLLED-TRIAL; WORKING-MEMORY; DOUBLE-BLIND; ANTIPSYCHOTIC-DRUGS; 1ST-EPISODE SCHIZOPHRENIA; PREFRONTAL CORTEX; NEGATIVE SYMPTOMS; ADD-ON; DOPAMINERGIC MODULATION; RECEPTOR ANTAGONIST;
D O I：
10.1007/s00115-009-2919-6
中图分类号：
R74 [神经病学与精神病学];
学科分类号：
摘要：
Cognitive deficits in schizophrenia are a clinically relevant symptom dimension and one of the best predictors for functional outcome. Pharmacological treatment of cognitive deficits in schizophrenia is still a challenge. The objective of this article is to present a detailed review of the literature on strategies for the pharmacological treatment of cognitive deficits. It is not clear whether first-generation antipsychotics have a genuine positive influence on cognition. There is only sparse evidence for the positive effect of second-generation antipsychotics on cognitive processes. Furthermore it is not evident that second-generation antipsychotics are more beneficial than first-generation antipsychotics in the treatment of cognitive deficits. The add-on use of substances which directly influence cognitive processes, so-called cognition-enhancing drugs is more promising.
引用
收藏
页码：564 / 576
页数：13
相关论文
共 50 条
  • [21] Cognitive Deficits in Schizophrenia: Understanding the Biological Correlates and Remediation Strategies
    Tripathi, Adarsh
    Kar, Sujita Kumar
    Shukla, Rashmi
    CLINICAL PSYCHOPHARMACOLOGY AND NEUROSCIENCE, 2018, 16 (01) : 7 - 17
  • [22] Pharmacological treatment of cognitive deficits in Alzheimer's disease
    Brodaty, H
    Ames, D
    Boundy, KL
    Hecker, J
    Snowdon, J
    Storey, E
    Yates, MW
    MEDICAL JOURNAL OF AUSTRALIA, 2001, 175 (06) : 324 - 329
  • [23] COGNITIVE DEFICITS IN SCHIZOPHRENIA
    GOLD, JM
    HARVEY, PD
    PSYCHIATRIC CLINICS OF NORTH AMERICA, 1993, 16 (02) : 295 - 312
  • [24] Cognitive Deficits in Schizophrenia
    Sunny, C.
    INDIAN JOURNAL OF PSYCHIATRY, 2020, 62 : S69 - S69
  • [25] Cognitive deficits in schizophrenia
    Berman, I
    PSYCHIATRIC ANNALS, 1999, 29 (11) : 621 - 621
  • [26] Cognitive Deficits in Schizophrenia
    Deborah J. Kayman
    Marjorie F. Goldstein
    Current Translational Geriatrics and Experimental Gerontology Reports, 2012, 1 (1): : 45 - 52
  • [27] Cognitive Deficits in Schizophrenia
    Kayman, Deborah J.
    Goldstein, Marjorie F.
    CURRENT GERIATRICS REPORTS, 2012, 1 (01): : 45 - 52
  • [28] Treatment of cognitive deficits in schizophrenia with atomoxetine: A case report
    Rao, Naren P.
    Venkatasubramanian, Ganesan
    Gangadhar, Bangalore N.
    JOURNAL OF CLINICAL PSYCHIATRY, 2007, 68 (12) : 1988 - 1989
  • [29] Novel leads in the treatment of schizophrenia with focus on cognitive deficits
    Svensson, T
    SCHIZOPHRENIA RESEARCH, 2006, 81 : 15 - 15
  • [30] Psychopharmacological treatment of cognitive deficits in Schizophrenia and mood disorders
    Vita, A.
    Mussoni, C.
    Deste, G.
    Ferlenghi, G.
    Turrina, C.
    Valsecchi, P.
    JOURNAL OF PSYCHOPATHOLOGY, 2018, 24 (02): : 62 - 72
12345